💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Viomycin

CHEMBL3085436 Phase 4 승인됨 Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
685.7 g/mol
LogP
-7.0
Phase
4

Viomycin is a cyclic peptide antibiotic produced by Streptomyces species that inhibits bacterial protein synthesis by binding to the 30S and 50S ribosomal subunits and blocking translocation, with particular activity against mycobacteria including Mycobacterium tuberculosis. It was used as a second-line antituberculosis agent for drug-resistant TB before the development of modern combination regimens. Its nephrotoxicity and ototoxicity limit its clinical application.

분자량

685.7000 g/mol

LogP

-7.00

TPSA

393.00 Ų

리핀스키 5의 법칙

불통과

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@H]([C@H]2C[C@H](O)NC(N)=N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48)/b13-7-/t10-,11+,12-,14-,15-,17-,18-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H43N13O10

                    

                    
                    

                        
HBD / HBA

                        
15 / 13

                    

                    
                    

                        
회전 가능 결합

                        
10

                    

                    
                    
                    

                        
무거운 원자

                        
48

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
Viomycin is a cyclic peptide antibiotic produced by Streptomyces species that inhibits bacterial protein synthesis by binding to the 30S and 50S ribosomal subunits and blocking translocation, with particular activity against mycobacteria including Mycobacterium tuberculosis. It was used as a second-line antituberculosis agent for drug-resistant TB before the development of modern combination regimens. Its nephrotoxicity and ototoxicity limit its clinical application.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Viomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3085436.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135398671.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.